Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

Benzer Materyaller

• Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
  Yazar:: Bailey, Clifford J, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin
  Yazar:: Del Prato, Stefano, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
  Yazar:: Fouqueray, Pascale, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
  Yazar:: Nauck, Michael A., ve diğerleri
  Baskı/Yayın Bilgisi: (2011)
• Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
  Yazar:: Ferrannini, Ele, ve diğerleri
  Baskı/Yayın Bilgisi: (2010)